This month, AACR's journals editors highlighted factors that may reduce pancreatic cancer risk, a new humanized mouse model, and more.
August’s edition of Editors’ Picks includes biomarkers of immunotherapy response, individualized colorectal screening guidelines, and other exciting research.
New cervical cancer self-screening options and a portable blood test device could lead to changes in at-home cancer screening and monitoring.
Clinical trials for dogs with cancer can extend the lives of our four-legged friends while revealing insights about cancer in humans.
The AACR journal editors' picks for July 2024 include a review of the risks from CAR T-cell therapy, advances made in sarcoma, and more.
Researchers are making progress on genetic classification of sarcoma tumors, the use of T-cell therapy, and nanomedicine delivery.
Immune checkpoint inhibitors are effective against non-small cell lung cancer in some patients. Researchers are investigating who benefits from the drugs and when they should be administered for maximum impact.
With the FDA’s approval of the first tumor‑infiltrating lymphocyte (TIL) therapy to treat advanced melanoma, researchers seek to expand this type of cellular therapy to other solid tumors.
The drug showed promise in treating small cell lung cancer that had progressed during or after chemotherapy.
The June edition of Editors’ Picks includes a clinical trial that clinched a new FDA approval for adagrasib, a new imaging modality to predict glioblastoma response, and more.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More